LONDON (Reuters) -AstraZeneca on Thursday beat expectations for its first -quarter revenue and income, helped by gross sales of a few of its oncology in addition to uncommon blood dysfunction medication.

The London-listed drugmaker, which experiences its leads to U.S. {dollars}, reported adjusted revenue of $1.92 per share on gross sales of about $10.9 billion.

Analysts on common had been anticipating $1.71 per share on gross sales of about $10.6 billion, in line with company-compiled consensus estimates.

The Anglo-Swedish drugmaker – one of many strongest performers amongst listed European pharma corporations – stood by its 2023 forecast on Thursday.

AstraZeneca (NASDAQ:)’s best-selling most cancers medication — Tagrisso, Imfinzi and Lynparza — generated $1.4 billion, $900 million and $651 million of gross sales, respectively, within the quarter.

Cowen analysts anticipated the three medication to herald about $1.45 billion, $735 million and $700 million respectively, in quarterly gross sales.

Different key medicines, such because the uncommon blood dysfunction drug Soliris and Ultomiris that got here with AstraZeneca’s $39 billion acquisition in 2021 of Alexion (NASDAQ:), generated gross sales of $834 million and $651 million, nicely forward Cowen estimates of $500 million and $400 million respectively.